Characterization and treatment of resistant hypertension

被引：3

作者：

Pisoni R. ^{[1
]}

Ahmed M.I. ^{[1
]}

Calhoun D.A. ^{[1
]}

机构：

[1] Vascular Biology and Hypertension Program, University of Alabama at Birmingham, 115 Community Health Services Building, Birmingham, AL 35294

来源：

Current Cardiology Reports | 2009年 / 11卷 / 6期

关键词：

Chronic Kidney Disease; Obstructive Sleep Apnea; Aldosterone; Renal Artery Stenosis; Telmisartan;

D O I：

10.1007/s11886-009-0059-z

中图分类号：

学科分类号：

摘要：

Resistant hypertension is a common medical problem. It carries a significantly increased risk of end-organ damage and cardiovascular events compared with more easily controlled hypertension. Resistant hypertension is most often related to isolated systolic hypertension and is characterized by aldosterone excess and increased intravascular volume. Its diagnosis requires the exclusion of pseudoresistance. The etiology of resistant hypertension is almost always multifactorial. Common reversible contributing factors need to be identified and addressed. Secondary causes of hypertension, such as primary aldosteronism, parenchymal and vascular kidney disease, and obstructive sleep apnea, require investigation and effective treatment if present. Therapy for resistant hypertension should be based on use of rational drug class combinations at optimal doses, with particular attention to adequate diuretic use. The addition of an aldosterone antagonist may further improve blood pressure control. © 2009 Springer Science+Business Media, LLC.

引用

页码：407 / 413

页数：6

共 45 条

[1]

Calhoun D.A., Jones D., Textor S., Et al., Resistant hypertension: Diagnosis, evaluation, and treatment: A scientific statement from the American Heart Association professional education committee of the council for high blood pressure research, Circulation, 117, (2008)

[2]

Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., Jones D.W., Materson B.J., Oparil S., Wright Jr. J.T., Roccella E.J., Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Hypertension, 42, 6, pp. 1206-1252, (2003)

[3]

Cushman W.C., Ford C.E., Cutler J.A., Et al., Success and predictors of blood pressure control in diverse North American settings: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT), J Clin Hypertens (Greenwich), 4, pp. 393-404, (2002)

[4]

Pepine C.J., Handberg E.M., Cooper-DeHoff R.M., Marks R.G., Kowey P., Messerli F.H., Mancia G., Cangiano J.L., Garcia-Barreto D., Keltai M., Erdine S., Bristol H.A., Kolb H.R., Bakris G.L., Cohen J.D., Parmley W.W., A Calcium Antagonist vs a Non-Calcium Antagonist Hypertension Treatment Strategy for Patients with Coronary Artery Disease the International Verapamil-Trandolapril Study (INVEST): A Randomized Controlled Trial, Journal of the American Medical Association, 290, 21, pp. 2805-2816, (20

[5]

Cuspidi C., Macca G., Sampieri L., Michev I., Salerno M., Fusi V., Severgnini B., Meani S., Magrini F., Zanchetti A., High prevalence of cardiac and extracardiac target organ damage in refractory hypertension, Journal of Hypertension, 19, 11, pp. 2063-2070, (2001)

[6]

Lewington S., Clarke R., Qizilbash N., Peto R., Collins R., Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies, Lancet, 360, 9349, pp. 1903-1913, (2002)

[7]

Salles G.F., Cardoso C.R., Muxfeldt E.S., Prognostic influence of office and ambulatory blood pressures in resistant hypertension, Arch Intern Med, 168, pp. 2340-2346, (2008)

[8]

Muxfeldt E.S., Cardoso C.R., Salles G.F., Prognostic value of nocturnal blood pressure reduction in resistant hypertension, Arch Intern Med, 169, pp. 874-880, (2009)

[9]

Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg [no authors listed], JAMA, 202, pp. 1028-1034, (1967)

[10]

Lloyd-Jones D.M., Evans J.C., Larson M.G., Et al., Differential control of systolic and diastolic blood pressure: Factors associated with lack of blood pressure control in the community, Hypertension, 36, pp. 594-599, (2000)

← 1 2 3 4 5 →